)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Kolon TissueGene
Kolon TissueGene (A950160) investor relations material
Kolon TissueGene Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary15 May, 2026
Executive summary
Focus on cell and gene therapy platform (TG-C) for osteoarthritis, with U.S. Phase 3 clinical trials completed for knee OA and Phase 2/1 approvals for hip OA and degenerative disc disease (DDD).
Revenue primarily from B2B technology out-licensing and health/beauty distribution; U.S. market entry and global expansion planned.
Significant R&D investment, with pipeline expansion into musculoskeletal and autoimmune diseases.
Financial highlights
Q1 2026 revenue: $963K (USD), down from $3.6M in 2025 and $3.7M in 2024.
Operating loss Q1 2026: $(3.7)M; net loss $(68.2)M, with negative EPS of $(4.09).
Cash and equivalents at Q1 2026: $62.7M; total assets $337.4M; equity $82.5M.
R&D expenses Q1 2026: $18.5M (1,923% of sales), reflecting heavy investment in clinical trials.
High debt ratio: liabilities $254.9M, equity $82.5M; debt-to-equity ratio 233%.
Outlook and guidance
Plans to file for FDA BLA after 2-year follow-up of Phase 3 knee OA trial.
Pipeline expansion into hip OA, DDD, rheumatoid arthritis, and animal health.
Commercialization strategy includes direct sales in the U.S. and licensing in other regions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kolon TissueGene
- Heavy R&D spending drives losses as Phase 3 knee OA trial completes and pipeline expands.A950160
Q3 20243 Jul 2026 - Revenue up 31% but net loss deepens; Phase 3 knee OA trials completed, BLA submission ahead.A950160Q4 20243 Jul 2026
- Losses narrowed as Phase 3 TG-C trials completed dosing; focus remains on FDA approval.A950160Q2 20243 Jul 2026
- Phase 3 dosing for TG-C completed; losses persist, but cash position strengthened.A950160Q1 20253 Jul 2026
- 2025 net loss widened to $135.4M as TG-C phase 3 trials completed dosing; BLA filing planned.A950160Q4 20253 Jul 2026
- H1 2025 saw $1.83M revenue, $(44.2)M net loss, and high R&D costs amid pivotal TG-C trials.A950160Q2 20253 Jul 2026
- TG-C Phase 3 completed; revenue down, net loss $(48.6)M, strong cash after capital raises.A950160Q3 20253 Jul 2026
Next Kolon TissueGene earnings date
Q2 202613 Aug, 2026
Kolon TissueGene
Next Kolon TissueGene earnings date
Q2 202613 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage